-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
| China's new crown drug candidate launches phase I clinical trials in the U. According to the announcement of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences on March 15th, the new drug candidate DC402234, a new anti-coronavirus (SARS-CoV-2) drug candidate, launched a phase I clinical trial in the United States on the same day. DC402234 is a new anti-SARS-CoV-2 candidate drug jointly developed by the teams of Liu Hong, Xu Yechun, and Jiang Hualiang from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the teams of Yang Haitao, Rao Zihe, Shanghai University of Science and Technology, and the teams of Zhang Leipi and Xiao Gengfu, Wuhan Institute of Virology, Chinese Academy of Sciences. Chinese Academy of Sciences Chinese Academy of Sciences Chinese Academy of Sciences Chinese Academy ofSciences Chinese Academy of Sciences According to reports, DC402234 is a peptidomimetic compound designed and synthesized based on the three-dimensional structure of the coronavirus main protease (M pro ). pro 5px;'>pro5px;'> pro 50 50 It is worth mentioning that on June 19, 2020, the top academic journal "Science" reported the above research results on the cover, and the research title is "Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease". A reporter from The Paper ( reported the results of the research at the time. pro It is reported that the results of this candidate new drug have reached an agreement on the transfer and transformation of results with the domestic enterprise Frontier Biopharmaceutical (Nanjing) Co. On March 15th, the US Phase I clinical study of DC402234 was officially launched, with Professor Gregory Tarcey from the Frontage Phase 1 Clinical Research Center in the US as the main researcher to advance the work. The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences stated that at present, DC402234 has not been approved for marketing in any country, and its safety and effectiveness in humans have not been confirmed, but it has been shown to beexcellentfor SARS-CoV-2 Mproin vitro. Chinese Academy of Sciences Chinese Academy of Sciences Chinese Academy of Sciencesproaspx?id=3570" style="color:#ba1413" target="_blank">focuses on the new crown pneumonia epidemic
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
Welcome to ECHEMI 
|
